Our earlier studies in SLE employing Dexamethasone or IFN-γ preconditioned MSCs have yielded significant disease ameliorating changes in the inflammatory profiles including reduction in autoantibodies, Th17 cytokines, Th17 cells, double negative T cells, inflammatory neutrophils population, organ pathology, organ physiology, improvement in T and B regulatory cells, and symptoms of alopecia, seizures, and limb inflammation. Here, IFNG is linked to systemic lupus erythematosus.